摘要
目的探讨钙离子拮抗剂贝尼地平对冠心病患者一氧化氮(NO)和内皮素(ET-1)的影响。方法将2006年1～7月对哈尔滨医科大学第四医院心内科36例冠心病患者给予贝尼地平2～4mg/d,治疗8周,测定用药前及服药后第4、8周NO和ET-1水平。以40名相匹配健康体检者为对照组给予安慰剂口服。结果冠心病患者的NO较对照组明显降低[(7.46±3.36)μmol/L对(33.49±12.45)μmol/L,P<0.05],ET-1升高[(79.60±10.04)ng/L对(59.50±6.28)ng/L,P<0.05]。贝尼地平治疗前后比较NO升高[(28.24±14.92)μmol/L对(7.46±3.36)μmol/L,P<0.01],ET-1降低[(60.01±13.84)ng/L对(79.60±10.04)ng/L,P<0.01]。结论贝尼地平能升高冠心病患者的NO水平,降低ET-1水平,从而证明贝尼地平具有内皮保护作用。
To search for the effect of benidipine,a kind of Ca^2＋ blocker,on NO and ET-I of patients with coronary heart disease. Methods Benidipine（2-4 rag/d）were given to the patients with coronary heart disease diag-nosed definitely for 8 weeks. Forty healthy candidates were enrolled in the control group,and their morning fasting blood were tested for NO and ET-I levels at the 4th,Sth week in order to compare with the control group. Results Blood NO level of CHD patients was lower and blood ET-I level was higher than the control group remarkably. After treatment NO level was increased and ET-I level was decreased separately. Conclusion Benidipine can increase NO level and de-crease ET-I level,which demonstrated the protective effect of benidipine for endothelia.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2007年第9期689-690,共2页
Chinese Journal of Practical Internal Medicine
